Skip to content
Home>Investor Relations>Blog>Balchem Corporation Completes Acquisition of Kappa Bioscience AS

Balchem Corporation Completes Acquisition of Kappa Bioscience AS

Posted: June 21, 2022
Blog | Investor Relations | Press Releases

Balchem Corporation announced that it completed its acquisition of Kappa Bioscience AS, a leading science-based manufacturer of specialty vitamin K2 for the human nutrition industry, headquartered in Oslo, Norway. The signing of a definitive agreement to acquire Kappa Bioscience AS was previously announced on June 14, 2022.

View Press Release

Related Posts

Balchem Corporation Reports Second Quarter 2022 Financial Results
Ted Harris, Chairman, CEO, and President of Balchem said, “The second quarter of 2022 was another excellent quarter for Balchem. We delivered very strong financial results with record sales and adjusted EBITDA in what remains a very difficult macro-economic and geo-political environment."
Balchem Announces Conference Call for Second Quarter 2022 Financial Results
Join Ted Harris, Chairman of the Board, CEO and President and Martin Bengtsson, CFO on Friday, July 29th at 11:00 AM Eastern Time (ET) to review 2nd Quarter 2022 results.